ACE2 and chronic obstructive pulmonary disease: To evaluate ACE2 protein stability, we exposed HLFs from non-smoker, smoker, and COPD subjects to cycloheximide (CHX 1 μg/mL), an inhibitor of protein synthesis [39], for up to 48 h, and assessed ACE2 protein expression by Western blot.